Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy

Without specific indication for chronic OAC due to concomitant CVD, a single antiplatelet agent is the basis for long-term antithrombotic treatment in aortic or peripheral arterial diseases.

Addition of another antiplatelet agent or low-dose anticoagulants is discussed based on ischaemic and bleeding risk and therapeutic paths (e.g. endovascular therapy).

The document cannot substitute multidisciplinary team discussions, particularly important with uncertain ischaemic/bleeding balance.

Regular reassessment of antithrombotic therapy is of paramount importance, as the balance evolves over time.